References
- 1. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: a clinician’s update. Am J Kidney Dis. 2011; 58(1): 118–126.10.1053/j.ajkd.2011.04.010
- 2. Freeman RB., Jr. The ‘indirect’ effects of cytomegalovirus infection. Am J Transplant. 2009; 9: 2453–2458.10.1111/j.1600-6143.2009.02824.x
- 3. Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013: CD003774.10.1002/14651858.CD003774.pub4
- 4. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010; 10: 1228–1237.10.1111/j.1600-6143.2010.03074.x
- 5. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003; 3 Suppl 4: 114–125.10.1034/j.1600-6143.3.s4.11.x
- 6. Selvey LA, Lim WH, Boan P, et al. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. BMC Infect Dis 2017; 17(1): 501.10.1186/s12879-017-2599-y
- 7. Florescu DF, Qiu F, Schmidt CM, Kalil AC. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis. 2014 Mar; 58(6): 785–803.10.1093/cid/cit945
- 8. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013; 85(5): 893–898.10.1002/jmv.23539
- 9. Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013; 26: 703–727.10.1128/CMR.00015-13
- 10. Martin-Gandul C, Perez-Romero P, Sanchez M, et al. Spanish network for research in infectious D: determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol. 2013; 56: 13–18.10.1016/j.jcv.2012.09.017
- 11. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013; 13: 93–106.10.1111/ajt.12103
- 12. Torre-Cisneros J, Aguado JM, Caston JJ et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando) 2016; 30: 119–143.10.1016/j.trre.2016.04.001
- 13. Halimi JM. Low-grade proteinuria and microalbuminuria in renal transplantation. Transplantation. 2013; 96(2): 121–130.10.1097/TP.0b013e31828719fb
- 14. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int. 2012; 25(9): 909–917.10.1111/j.1432-2277.2012.01500.x
- 15. Liang X, Famure O, Li Y, Kim SJ. Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis. Prog Transplant. 2018; 28(2): 124–133.10.1177/1526924818765798
- 16. Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation. 2019 Feb 19.10.1097/TP.0000000000002626
- 17. Vilibic-Cavlek T, Kolaric B, Bogdanic M, Tabain I, Beader N. Herpes Group Viruses: a Seroprevalence Study in Hemodialysis Patients. Acta Clin Croat. 2017; 56(2): 255–261.10.20471/acc.2017.56.02.08